Rapid response to emerging diseases is critical when developing a vaccine. Synthetic RNA platforms (mRNA and saRNA) are at the forefront of novel vaccine development programs.
Note: saRNA products are classified by Aldevron under ECCN 1C351a.55 on the Commerce Control List set forth in the US Export Administration Regulations (EAR), which is highly controlled for purposes of export outside the United States. If the product is requested to be shipped outside the US, an export license from US Dept. of Commerce’s Bureau of Industry and Security is required before the product may be shipped.
1Bloom, K., van den Berg, F. & Arbuthnot, P., 2020. Self-amplifying RNA vaccines for infectious diseases. Gene therapy.
2Vogel, A.B. et al., 2018. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Molecular therapy: the journal of the American Society of Gene Therapy, 26(2), pp.446–455.